National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

basiliximab
A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Simulect
Code name:SDZ-CHI-621



Previous:baclofen/amitriptyline/ketamine gel, Bactrim, Bag Balm, barium sulfate, Barseb HC
Next:BAY 56-3722, BayGam, BB-10901, BCG vaccine, bcr-abl (b2a2)-derived peptide vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov